---
figid: PMC11083102__cancers-16-01690-g004
figtitle: Key signaling pathways for FDA-approved molecular-directed drugs for the
  treatment of advanced CCA in the palliative setting
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11083102
filename: cancers-16-01690-g004.jpg
figlink: /pmc/articles/PMC11083102/figure/F4
number: F4
caption: Key signaling pathways for FDA-approved molecular-directed drugs for the
  treatment of advanced CCA in the palliative setting. (A) FGFR signaling pathway.
  (B) IDH signaling pathway. (C) Mechanism of immune checkpoint inhibition. (D) NTRK
  signaling pathway. 1 Durvalumab/pembrolizumab in combination with gemcitabine/cisplatin
  for all-comers, pembrolizumab monotherapy for MSI-high/TMB-high. Created and modified
  with Biorender
papertitle: Current and Future Therapeutic Targets for Directed Molecular Therapies
  in Cholangiocarcinoma
reftext: Philipp Heumann, et al. Cancers (Basel). 2024 May;16(9).
year: '2024'
doi: 10.3390/cancers16091690
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: cholangiocarcinoma | targeted therapy | biliary tract cancer | molecular-directed
  therapy
automl_pathway: 0.9315548
figid_alias: PMC11083102__F4
figtype: Figure
redirect_from: /figures/PMC11083102__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11083102__cancers-16-01690-g004.html
  '@type': Dataset
  description: Key signaling pathways for FDA-approved molecular-directed drugs for
    the treatment of advanced CCA in the palliative setting. (A) FGFR signaling pathway.
    (B) IDH signaling pathway. (C) Mechanism of immune checkpoint inhibition. (D)
    NTRK signaling pathway. 1 Durvalumab/pembrolizumab in combination with gemcitabine/cisplatin
    for all-comers, pembrolizumab monotherapy for MSI-high/TMB-high. Created and modified
    with Biorender
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HSPG2
  - PLCE1
  - PLCZ1
  - PLCB1
  - PLCB2
  - PLCB3
  - PLCB4
  - PLCD1
  - PLCD3
  - PLCD4
  - PLCG1
  - PLCG2
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - ZSWIM2
  - IDH2
  - IDH1
  - DECR1
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - EPHB2
  - MAPK1
  - MAPK3
  - AKT1
  - AKT2
  - AKT3
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - STAT3
  - H1-0
  - H1-1
  - H1-2
  - H1-3
  - H1-4
  - H1-5
  - H1-6
  - H1-7
  - H1-8
  - H1-10
  - .na.character
  - H2AB1
  - H2AJ
  - H2AZ2
  - H2AX
  - MACROH2A1
  - MACROH2A2
  - H2AZ1
  - H2AC1
  - H2AC6
  - H2AC7
  - H2AC12
  - H2AC14
  - H2AC21
  - H2AC20
  - H2AC25
  - H2BC1
  - H2BC3
  - H2BC5
  - H2BC9
  - H2BC11
  - H2BC12
  - H2BC13
  - H2BC14
  - H2BC15
  - H2BC17
  - H2BC18
  - H2BC19P
  - H2BC20P
  - H2BC21
  - H2BC26
  - H2BC12L
  - H2BW2
  - H2BW1
  - H3-4
  - H3-5
  - H4C7
  - NTRK1
  - NTRK2
  - NTRK3
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CD274
  - RPL29P31
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - NADP+
  - NADPH
  - Ivosidenib
  - 2-Hydroxyglutarate
---
